About BeiGene
BeiGene is a Chinese life sciences biotechnology company based in Beijing that is focused on discovering and developing innovative oncology drugs that will address unmet medical needs in cancers that are prevalent in China and the Asia-Pacific region.
Our compound portfolio will encompass novel drugs that evolve out of our discovery laboratories in China and those selected from in-licensing partners for their potential to have high impact in the treatment of Chinese and Asian cancers.
To complement our discovery and development capabilities, BeiGene is creating a robust platform in China to enable the identification of specific subsets of patient populations that will identify patients who are most likely to benefit from the use of specific drugs or treatments. Understanding the link between treatment sensitivity and molecular targets will direct us to develop future drug candidates with greater efficacy and safety.
We are building core excellence in:
1.novel drug discovery in the areas of both small molecules and biologicals
2.translational research with an emphasis on biomarker identification and validation in patients
3.bioinformatics based on human tumor genotyping and expression profiling
4.clinical development
Our unique organization synergistically combines the strengths of:
1.Chinese and Western scientific knowledge and medical practice
2.rigor and robustness from large pharma with biotech entrepreneurialism
3.Chinese and western start-up culture
BeiGene is headquartered and operates from Beijing, China and has an office in Philadelphia, USA.
Beijing Office
No.30 Science Park Road
Zhong-Guan-Cun Life Science Park
Changping district
Beijing P.R.China
102206
